TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021

NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.

Brian D Weiss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.